PTE - PolarityTE, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
8.18
-0.26 (-3.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 8.44
Open 8.47
Bid 0.00 x 1800
Ask 0.00 x 1000
Day's Range 7.93 - 8.49
52 Week Range 7.93 - 41.22
Volume 527,987
Avg. Volume 363,435
Market Cap 194.43M
Beta (3Y Monthly) 1.81
PE Ratio (TTM) N/A
EPS (TTM) -5.18
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date 2016-01-12
1y Target Est 34.33
Trade prices are not sourced from all markets
  • Why PolarityTE Is Sinking Today
    Motley Fool 8 days ago

    Why PolarityTE Is Sinking Today

    Shares drop after the company announces that it is raising capital. Here are the must-know details for investors.

  • PolarityTE Announces Pricing of Public Offering of Common Stock
    PR Newswire 8 days ago

    PolarityTE Announces Pricing of Public Offering of Common Stock

    SALT LAKE CITY, April 10, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today the pricing of an underwritten public offering of approximately $27.5 million of shares of its common stock. In addition, PolarityTE has granted the underwriter a 30-day option to purchase up to $4,125,000 of additional shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.

  • PolarityTE Announces Public Offering of Common Stock
    PR Newswire 9 days ago

    PolarityTE Announces Public Offering of Common Stock

    SALT LAKE CITY, April 9, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, PolarityTE intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock at the price to the public, less underwriting discounts and commissions. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.

  • PR Newswire 16 days ago

    Lifshitz & Miller LLP Announces Investigation of Bloom Energy Corporation, First Choice Healthcare Solutions, Inc., Nutanix, Inc., PolarityTE, Inc., Revlon, Inc., Tivity Health, Inc., WellCare Health Plans, Inc., and Whitestone REIT

    NEW YORK , April 2, 2019 /PRNewswire/ -- Bloom Energy Corporation (BE) Lifshitz & Miller   announces investigation into possible securities laws violations in connection with BE's IPO at $15.00 per share. ...

  • PolarityTE Enrolls First Patients in Two Clinical Trials Evaluating SkinTE for the Treatment of Chronic Wounds
    PR Newswire 17 days ago

    PolarityTE Enrolls First Patients in Two Clinical Trials Evaluating SkinTE for the Treatment of Chronic Wounds

    SALT LAKE CITY, April 1, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that patient enrollment has begun for two new randomized controlled trials evaluating SkinTE™ for the treatment of chronic wounds, specifically diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). SkinTE is commercially available through a regional market release and is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for skin repair, reconstruction and replacement. The Company's two randomized controlled trials will be led by the principal investigator David G. Armstrong, DPM, MD, PhD, Professor of Surgery at the University of Southern California, founder of the Southwestern Academic Limb Salvage Alliance, and a world expert in wound healing and limb preservation.

  • PolarityTE Announces Richard Hague, Formerly from Sanofi, Genzyme and Recently Anika Therapeutics as Chief Operating Officer
    PR Newswire 20 days ago

    PolarityTE Announces Richard Hague, Formerly from Sanofi, Genzyme and Recently Anika Therapeutics as Chief Operating Officer

    SALT LAKE CITY, March 29, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that Richard Hague will join as the Company's Chief Operating Officer on April 8, 2019. Mr. Hague brings to PolarityTE experience in many aspects of corporate development and operations from his more than 30-year career in the biotechnology industry, including launching a variety of autologous cell and tissue therapies. Current COO Ned Swanson, MD, will continue on as PolarityTE's Chief Translational Medicine Officer.

  • Clinical Outcomes Data on SkinTE™ from Lower Extremity Chronic Wounds to be Presented at Diabetic Limb Salvage (DLS) Conference
    PR Newswire 22 days ago

    Clinical Outcomes Data on SkinTE™ from Lower Extremity Chronic Wounds to be Presented at Diabetic Limb Salvage (DLS) Conference

    SALT LAKE CITY, March 27, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that two clinical outcomes abstracts on SkinTE™ for the treatment of diabetic foot ulcers (DFUs) will be presented at the Diabetic Limb Salvage (DLS) Conference in Washington, DC being held on April 4-6, 2019. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of patient's own skin. One of the abstracts, which includes data from the pilot study for a randomized controlled trial evaluating SkinTE for DFUs, has been recognized with a Top Abstract Special Designation.

  • PolarityTE Hosts Symposium Featuring SkinTE-Treated Burn Survivor, New Clinical Data at American Burn Association Annual Meeting
    PR Newswire 28 days ago

    PolarityTE Hosts Symposium Featuring SkinTE-Treated Burn Survivor, New Clinical Data at American Burn Association Annual Meeting

    SALT LAKE CITY, March 21, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today it will host a symposium at the American Burn Association (ABA) 51st Annual Meeting featuring a burn survivor who will share her story after being treated with the Company's SkinTE™ product. The Company's symposium is Wednesday, April 3, from 7-8:30 p.m. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for skin repair, reconstruction and replacement.

  • PolarityTE to Present at Oppenheimer 29th Annual Healthcare Conference
    PR Newswire last month

    PolarityTE to Present at Oppenheimer 29th Annual Healthcare Conference

    SALT LAKE CITY , March 19, 2019 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: PTE)   announced today that it will attend and present at the Oppenheimer 29 th Annual Healthcare Conference on March 20, 2019 ...

  • RM LAW Announces Investigation of PolarityTE, Inc.
    PR Newswire last month

    RM LAW Announces Investigation of PolarityTE, Inc.

    BERWYN, Pa. , March 19, 2019 /PRNewswire/ --  RM LAW, P.C. announces an investigation on behalf of PolarityTE, Inc. (NASDAQ: PTE) ("PolarityTE" or the "Company") investors concerning ...

  • Business Wire last month

    Federman & Sherwood Investigates PolarityTE, Inc. for Possible Violations of Federal Securities Laws

    The law firm of Federman & Sherwood has initiated an investigation into PolarityTE, Inc. (PTE) with respect to possible violations of federal securities laws. PTE, Inc. is headquartered in Salt Lake City, Utah. On March 18, 2019, PTE disclosed that “[o]n March 4, 2019, we obtained from the SEC a copy of the formal order of investigation of the Company and its affiliates with respect to possible violations of the federal securities laws, including, among other things, the anti-fraud provisions of the Securities Act and the Exchange Act with respect to the Company’s public disclosures, the beneficial ownership reporting provisions of the Exchange Act and the anti-price manipulation provisions of the Exchange Act.” On this news, shares of PTE fell $2.42 per share, or over 15%, to close at $13.05 per share on March 18, 2019, damaging investors.

  • GlobeNewswire last month

    PolarityTE (PTE) Investigation: Bernstein Liebhard LLP Announces Investigation of PolarityTE, Inc. - PTE

    Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of PolarityTE, Inc. (“PolarityTE” or the “Company”) (PTE) resulting from allegations that PolarityTE and/or its executives may have issued materially misleading business information to the investing public. If you purchased PolarityTE securities, and/or would like to discuss your legal rights and options, please visit PolarityTE Shareholder Investigation or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.

  • GlobeNewswire last month

    Bragar Eagel & Squire, P.C. is Investigating PolarityTE, Inc. (PTE) on Behalf of Stockholders and Encourages PTE Investors to Contact the Firm

    NEW YORK, March 18, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against PolarityTE, Inc. (NASDAQ: PTE). Our investigation concerns whether.

  • PolarityTE (PTE) Investigation: Bernstein Liebhard LLP Announces Investigation Of PolarityTE, Inc. - PTE
    PR Newswire last month

    PolarityTE (PTE) Investigation: Bernstein Liebhard LLP Announces Investigation Of PolarityTE, Inc. - PTE

    NEW YORK , March 18, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of PolarityTE, ...

  • Why PolarityTE Stock Tanked Today
    Motley Fool last month

    Why PolarityTE Stock Tanked Today

    Shares plunge after the company reports fourth-quarter results. Here's what investors need to know.

  • CNBC last month

    Biotech's shares tumble after it says SEC is looking into possible manipulation

    PolarityTE said the SEC subpoenaed it earlier this month for documents related to any promotion of the company or its securities, among other items.

  • PolarityTE Reports Results and Corporate Update for Two-Month Transition Period Ended December 31, 2018
    PR Newswire last month

    PolarityTE Reports Results and Corporate Update for Two-Month Transition Period Ended December 31, 2018

    SALT LAKE CITY , March 18, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, ...

  • Read This Before Buying PolarityTE, Inc. (NASDAQ:PTE) Shares
    Simply Wall St. last month

    Read This Before Buying PolarityTE, Inc. (NASDAQ:PTE) Shares

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examplesRead More...

  • PolarityTE to Attend Medlab Asia Pacific and Asia Health 2019 Conferences
    PR Newswire last month

    PolarityTE to Attend Medlab Asia Pacific and Asia Health 2019 Conferences

    SALT LAKE CITY, March 13, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) announced today that it will attend the Medlab Asia Pacific and Asia Health 2019 conferences in Singapore from March 26-28, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.

  • Why PolarityTE Stock Is Shooting Higher Today
    Motley Fool last month

    Why PolarityTE Stock Is Shooting Higher Today

    Traders cheered after some positive regulatory news emerged.

  • Will Polarity (PTE) Report Negative Q1 Earnings? What You Should Know
    Zacks last month

    Will Polarity (PTE) Report Negative Q1 Earnings? What You Should Know

    Polarity (PTE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PolarityTE to Present at the 39th Annual Cowen Healthcare Conference and at the 13th Annual Canaccord Genuity Musculoskeletal Conference
    PR Newswire last month

    PolarityTE to Present at the 39th Annual Cowen Healthcare Conference and at the 13th Annual Canaccord Genuity Musculoskeletal Conference

    SALT LAKE CITY, March 6, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) announced today that it will attend and present at the Cowen 39th Annual Healthcare Conference on March 11, 2019 in Boston, MA and the 13th Annual Canaccord Genuity Musculoskeletal Conference on March 12, 2019 in Las Vegas, NV.

  • Congressional Health Care Innovation Showcase to Feature PolarityTE
    PR Newswire last month

    Congressional Health Care Innovation Showcase to Feature PolarityTE

    SALT LAKE CITY, March 5, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) announced today that its platform technology will be featured at the U.S. House of Representatives' Health Care Innovation Showcase in Washington, DC on March 7, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The Health Care Innovation Showcase is organized by the Health Care Innovation Caucus led by U.S. Representatives Mike Kelly (R-PA), Ron Kind (D-WI), Markwayne Mullin (R-OK) and Ami Bera, M.D. (D-CA).

  • PolarityTE Presents Platform Technology at Department of Defense Pacific Operational Science and Technology (POST) Conference
    PR Newswire 2 months ago

    PolarityTE Presents Platform Technology at Department of Defense Pacific Operational Science and Technology (POST) Conference

    SALT LAKE CITY, Feb. 27, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) announced today that its platform technology will be featured at the 2019 Pacific Operational Science and Technology (POST) Conference, co-sponsored by the United States Indo-Pacific Command and TechConnect, held March 4-8, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Two poster presentations that highlight the regenerative capacities of the PolarityTE platform technology will be presented during the conference.

  • Zacks.com featured expert Kevin Matras highlights: Shenandoah Telecommunications, Honda Motor, PolarityTE, Ubiquiti Networks and Titan Machinery
    Zacks 2 months ago

    Zacks.com featured expert Kevin Matras highlights: Shenandoah Telecommunications, Honda Motor, PolarityTE, Ubiquiti Networks and Titan Machinery

    Zacks.com featured expert Kevin Matras highlights: Shenandoah Telecommunications, Honda Motor, PolarityTE, Ubiquiti Networks and Titan Machinery